Agilent mmr ihc panel pharmdx (dako omnis) receives fda approval as a companion diagnostic test for colorectal cancer

Santa clara, calif.--(business wire)--agilent technologies inc. (nyse: a) today announced that its mmr ihc panel pharmdx (dako omnis) has received fda approval as a companion diagnostic (cdx) test for colorectal cancer. this test aids in identifying mismatch repair deficient (dmmr) colorectal cancer (crc) patients who are eligible for treatment with bristol myers squibb's opdivo® (nivolumab) alone or opdivo (nivolumab) in combination with yervoy® (ipilimumab). the mmr ihc panel pharmdx (dako om.
A Ratings Summary
A Quant Ranking